1. Academic Validation
  2. Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development

Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development

  • Int J Biol Macromol. 2024 Oct;278(Pt 3):134844. doi: 10.1016/j.ijbiomac.2024.134844.
Rong Wang 1 Yu Pan 2 Lan Zhang 2 Jun Wang 3 Jiang Ni 4 Yang Ding 5 Shaopeng Wang 6 Jian Yin 7 Lingwen Ding 8 Xuebin Ran 9 Shuangyi Fan 10 Qiaoyang Sun 11 Soo Yong Tan 10 H Phillip Koeffler 12 Jie Li 13 Yuanyuan Mi 14 Yong Q Chen 15
Affiliations

Affiliations

  • 1 MOE Medical Basic Research Innovation Center for Gut Microbiota and Chronic Diseases, Wuxi School of Medicine, Jiangnan University, Wuxi, China; School of Food Science and Technology, Jiangnan University, Wuxi, China.
  • 2 MOE Medical Basic Research Innovation Center for Gut Microbiota and Chronic Diseases, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
  • 3 First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing, China; Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi, China.
  • 4 Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi, China.
  • 5 College of Pharmacy, Pharmaceutical Series, China Pharmaceutical University, Nanjing, China.
  • 6 Jiangnan University Medical Center, Jiangnan University, Wuxi, China.
  • 7 Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology & School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, China.
  • 8 Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore; Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • 9 Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • 10 Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • 11 Department of Neurology, National Neuroscience Institute, Singapore General Hospital, Singapore, Singapore.
  • 12 Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore; Division of Hematology/Oncology, Cedars-Sinai Medical Center, UCLA School of Medicine, CA, Los Angeles, USA.
  • 13 First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing, China. Electronic address: drc_lijie@126.com.
  • 14 Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi, China. Electronic address: miniao1984@163.com.
  • 15 MOE Medical Basic Research Innovation Center for Gut Microbiota and Chronic Diseases, Wuxi School of Medicine, Jiangnan University, Wuxi, China; School of Food Science and Technology, Jiangnan University, Wuxi, China. Electronic address: yqchen@jiangnan.edu.cn.
Abstract

Stachyose (STA) is a prebiotic with poor oral bioavailability. In this study, we developed stachyose caproate (C6-STA), as a novel STA derivative, to demonstrate its high adsorption rate via oral administration. Pharmacokinetic analysis reveals that after absorption, the STA derived from C6-STA reaches its highest peak in the blood, liver, and kidney at 20 min, 30 min, and 12-24 h, with approximate levels of 1200 μg/mL, 0.14 μg/mL, and 0.2-0.3 μg/mL, respectively. In addition, the accumulation of STA in prostate tissues of mice with castration-resistant prostate Cancer (CRPC) (1.75 μg/mg) is 10-fold higher than that in normal prostate tissues (0.14 μg/mg). The analysis also reveals that C6-STA has t1/2 of 12.8 h and Tmax of 0.25 h, indicating that it has the potential to be used as a promising drug in clinical practice. The toxicological evaluation shows no obvious side effects of C6-STA in mice administered with a 0.2 g/kg intragastric dose. Pharmacodynamic analysis and mechanism investigation of C6-STA show its ability to inhibit peroxiredoxin 5 (PRDX5) Enzyme activity, disrupt PRDX5-nuclear factor erythroid 2-related factor 2 (NRF2) interaction, and decrease NAD(P)H quinone dehydrogenase 1 (NQO1) levels. NQO1 decrease further causes the accumulation of quinone radicals, which ultimately leads to the Apoptosis of LNCaP cell-derived drug-tolerant persister (DTP) cells and slows CRPC progression. Our study discovered the anti-tumor activity of stachyose and shows that prebiotics have biological functions in vivo besides in the gut. Further investigation of C6-STA, especially in CRPC patients, is warranted.

Keywords

Castration-resistant prostate cancer; Drug-tolerant persister; Nuclear factor erythroid 2-related factor 2; Peroxiredoxin 5; Stachyose; Stachyose caproate.

Figures
Products